In the first quarter of this year, with its technological advantages and continuous product innovation capabilities, Tianjin Hoyotek Biomedical Co., Ltd. (hereinafter referred to as “Hoyotek”) handed in a brilliant report card: the self-developed chemiluminescence platform products and fluorescence platform combined detection products for three tumor screening items including thymidine kinase 1 (TK1), vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) were granted certificates of registration, achieved the multi-index coverage of early tumor screening, and became the world's first kind of fluorescence immunochromatography triple-combined detection products for early tumor screening; the alpha-fetoprotein (AFP) assay kits and the total prostate specific antigen (t-PSA) assay kits in the early tumor screening set were newly granted class III certificates of registration; a glycan hemoglobin - C-peptide combined detection kit, the first domestic glycan hemoglobin and C-peptide two-index combined test product, got the national invention patent...

Hoyotek Biomedical was settled in Tianjin Port Free Trade Zone in August 2020. At the end of 2022, Hoyotek laid out a new track for in vitro diagnosis, and invested in and established Hongmeng Medical Research Center, specializing in production under the registrant system, CRO and CDMO services. At present, Hoyotek has more than 100 detection products covering early tumor screening, senile dementia and brain injury, cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes and reproductive diseases, etc.

In vitro diagnosis or IVD means a diagnostic method that detects body fluids, cells, tissues and other samples in vitro to obtain clinical diagnosis information and then determine diseases or body functions. It is an important source of clinical diagnosis information, can provide important reference index for doctors’ treatment and medication, and has become an indispensable tool for modern disease and health management. The Action Plan of Cancer Prevention and Control (2023-2030) issued by the National Health Commission clearly proposes to promote early diagnosis and early treatment of cancers, strengthen the long-term mechanism of screening, and make the innovation and application of cancer early screening technologies a key link of cancer prevention and treatment.

Under the influence of the big health strategy, the in vitro diagnosis industry in China has developed rapidly in recent years. All provinces and cities across the country have successively introduced charging standards and promoted the market application of in vitro diagnosis. At present, Hoyotek's early tumor screening products are gradually being widely used in the country. For example, “the chemiluminescence platform products and fluorescence platform triple-combined detection products for TK1, VEGF and CEA tumor screening items” have been applied in hospitals and physical examination institutions at different levels including some Grade-A tertiary hospitals. As three important tumor markers, TK1, VEGF and CEA, when detected in a combined manner, can reflect the tumor growth, metastasis and invasion more comprehensively, thus improving the accuracy and reliability of detection.

With the improvement of health awareness and medical care, tumor detection, as an important detection way to prevent and treat diseases, is recognized and accepted by more and more people. “Traditional tumor detection often relies on a single index, which limits its accuracy and reliability. Therefore, the combined detection of multiple tumor markers has become a hot spot and trend in current research,” said Wu Bo, executive director and general manager of Hoyotek. “To stabilize and reinforce the business of in vitro diagnostic reagents, Hoyotek will continue to intensify research and development, launch more tumor detection kits with excellent performance at reasonable prices, provide users with accurate and reliable detection services, and seek close cooperation with more in vitro diagnosis enterprises, detection centers and pharmaceutical companies to integrate resources, give full play of complementary advantages and jointly facilitate clinical tests to better assist disease diagnosis and treatment.”

On the “fast track” of rapidly developing in vitro diagnosis industry, Hoyotek implements the “products + instruments” integration strategy, provides one-stop solutions, improves customer viscosity and market competitiveness, actively expands the international markets and accelerate the localized operation of overseas markets. In terms of product research and development, Hoyotek will carry out research and development and technological innovation in the research areas such as gastric Helicobacter pylori typing, respiratory diseases, gynecological inflammation, Alzheimer, and hand, foot and mouth diseases, and strive to fill a gap in the market unoccupied by Roche, Abbott, Siemens and Beckmann. In addition, Hoyotek will continue to innovate products, actively develop differentiated products, expand CRO business, carry out technology platform innovation, research and develop antigens, antibodies and magnetic bead raw materials, and innovate the core materials.

Biomedical industry is one of the strategic emerging industries cultivated and developed by Tianjin Municipality. Over the years, the Free Trade Zone has, always adhering to the concept of “Party leadership and joint creation”, been committed to promoting scientific and technological innovation and industrialized development, striven to create new drivers of economic development, vigorously developed the bio-pharmaceutical industry, and continued to optimize the business environment. In the future, Tianjin Port Free Trade Zone will continue to gather strength to tackle the breakthroughs of original and leading technologies, comprehensively stimulate the vitality of scientific and technological innovation, accelerate the formation of new quality productive forces, and promote high-quality industrial development, in order to make contributions to the construction of Tianjin into a beautiful “coastal city” and a modern socialist metropolis.